Here are five takeaways:
1. The stock has a price target of $178.47 for March 30, which is 67 percent above $106.87 share price.
2. If the $178.47 price target is reached, the $39.82 billion company will be worth $26.68 billion more.
3. Out of 22 analysts covering Stryker, 18 rate it “buy,” two rate it “sell,” while nine rate it “hold.”
4. Since March 9, 2015, the stock has seen nine insider sales totaling $9.92 million in net activity.
5. Just yesterday, Stryker Director Ronda E. Stryker sold 12,000 shares of the company’s stock for a total of $1.25 million.
More articles on devices:
InVivo continues to see success with INSPIRE study—5 observations
Stryker gears up its challenge at first stop on PGA Tour: 3 notes
Amedica, Stryker, SI-BONE & & more: 12 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
